Gilead's Pricing Strategy Faces New Opposition Tactics: Patent, Antitrust Suit
This article was originally published in The Pink Sheet Daily
AIDS Healthcare Foundation claims patents covering drug in Genvoya combo are invalid and that Gilead's exclusive licensing deals constitute barriers to trade; Massachusetts AG may pursue unfair trade practice action over Sovaldi pricing.
You may also be interested in...
US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.
Senate Special Aging Committee hearing Wednesday to focus on price spikes in off-patent drugs without testimony from drug makers.
In response to price concerns with Sovaldi, Gilead Sciences emphasized that “Medicaid, by law, receives very deep discounts, and Gilead is working with each state to complete the necessary steps to ensure a timely review and addition to the state formulary.”